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The dataset presented in this article is related to the research
article entitled “Detection of HER2 Gene Polymorphism in Breast
Cancer: PCR Optimization Study” (B.R. Budiarto, Desriani, 2016) [1]
with some modiﬁcation in primers used and in PCR optimization
strategy to eliminate false-positive result that may occur in
HER2I655V polymorphism detection. Combining a new set of pri-
mers with PCR gradient, The allele-speciﬁc PCR well performs to
detect all type of breast cancer-originated HER2I655V genotypes.
The validation of this method was done using Sanger DNA
sequencing, offering an alternative tool for HER2I655V polymorph-
ism detection in another type of cancer.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaMolecular Biology, Cancer researchype of data Table and ﬁgurevier Inc. This is an open access article under the CC BY license
gerodes@yahoo.com (B.R. Budiarto), desrianilipi@gmail.com,
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B.R. Budiarto, Desriani / Data in Brief 9 (2016) 689–695690ow data was
acquiredPCR, DNA sequencing and statistics analysisata format Raw, analyzed
xperimental factors DNA was extracted form frozen section of breast cancer tissue
xperimental
featuresAllele-Speciﬁc PCR using two spesiﬁc primer (Forward direction) and one
common primer (revere direction) to detect HER2I655V polymorphismata source location Research Center for Biotechnology, Indonesian Institute of Science (LIPI),
Indonesiaata accessibility Data is available with this articleD
Value of the data
 The data provide a straightforward strategy for clarifying the possibility of a false-positive
ampliﬁcation generated by allele-speciﬁc PCR.
 The data provide the technique to determine the proper dosage of DNA template used in allele-
speciﬁc PCR for the success of HER2I655Vgenotyping.
 Data comparison of HER2I655V polymorphism between our improved allele-speciﬁc PCR with
Sanger DNA sequencing is provided in a way to validate the method easily.
 Allele frequency data for breast cancer –related HER2I655V polymorphism can be used as a reference
for researchers who conduct similar experiments for HER2I655V polymorphism studies with breast
cancer risk related to speciﬁc demography or other races.1. Data
The detection of breast cancer-related HER2I655V polymorphism using allele-speciﬁc PCR using
mismatch-speciﬁc primers strategy as shown in Fig. 1. The optimum annealing temperature for breast
cancer-related HER2I655V genotyping in allele-speciﬁc PCR was done using gradient PCR strategy with
SNP-known DNA template (Fig. 2). To test sensitivity of the method, we used two types of genomic
DNA which contain AA genotype or AG genotype in HER2 gene as allele representative with diluted
ranging from 0.019 up to 10 ng of the template at optimized PCR condition (Fig. 3). Then, the relia-
bility of allele-speciﬁc PCR was compared with data of Sanger DNA sequencing by looking the con-
sistency of HER2I655V genotypes data between two methods (Fig. 4 and Table 1). The allele frequency
of breast cancer-originated HER2I655V obtained from allele-speciﬁc PCR was similar with an allele
frequency data of breast cancer-originated HER2I655V from Asian population (Table 2).2. Experimental design, materials and methods
2.1. Sample collection and genomic DNA extraction
Sixty-one breast cancer tissues from archived biopsies as the frozen section were collected fromM.
Djamil Hospital Padang, West Sumatera Province. Genomic DNA was then extracted followed manual
tissue DNA extraction protocol (Pure Link Genomic DNA Mini Kit; Invitrogen). We have also prepared
two types of genomic DNA with SNPs have previously been determined using a Sanger DNA
sequencing method. No.6 tissue-retrieved genomic DNA with HER2 gene carries AG genotype while
DEV (abbreviaton of patient's name) tissue-retrieved genomic DNA with HER2 gene carries AA gen-
otype. All subjects enrolled in this experiment were approved by the local ethics committee, issued by
the Ministry of Health, Republic of Indonesia.
2.2. Allele-speciﬁc PCR optimization
The optimum annealing temperature for allele-speciﬁc PCR was determined using genomic DNA
with known SNPs. Each of 12.5 mL reaction mixture was contained 11.25 mL of PCR Super Mix
M    1 2 3 4 5 6 7 8
54.3oC 54.9oC 57.3oC 59.7oC 60.8oC 62.3oC
M     1 2 3 4 5 6 7 8 M     1 2 3 4 5 6 7 8
Fig. 2. Determination of the best annealing temperature for allele-speciﬁc PCR in typing HER2I655V polymorphism. Lane 1, 3,
5 and 7 are PCR products of AG genotype (142 bp and 168 bp), lane 2 and 6 are PCR products of AA genotype (142 bp), and lane
4 and 8 are NTC (Non-Template Control). No.6 genomic DNA was used as DNA template for AG genotype, while DEV genomic
DNA was used as DNA template for AA genotype. M is 100 bp DNA ladder. The PCR product was run on 3% agarose under UV
illumination.
Fig. 1. Illustration of allele-speciﬁc PCR and its primers design and position towards target HER2I655V polymorphism.
Nucleotides with red color at 30 end of primer indicate the mismatched base pairing that correspond to SNP site. Nucleotides
with green color at 3rd position indicate the mismatched base pairing to increase SNP discrimination level. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
B.R. Budiarto, Desriani / Data in Brief 9 (2016) 689–695 691(Invitrogen), 0.1 mM of allele-speciﬁc forward primer (50-CCAGCCCTCTGACGTCCAGCA-30), 0.06 mM of
long allele-speciﬁc forward primer (50-GCGGGCAGGGCGGCGGGGGCGGGGCCCCAGCCCTCTGACGTC-
CACCG-30), 0.15 mM of reverse primer (50-TCCGTTTCCTGCAGCAGTCTCC-30), and 0.25 ml (3–6 ng) of
DNA template. The Primers ratio used in this experiment followed the optimized PCR method as
suggested by Germer and Higuchi, [2] and Gaundet et al. [3] with minor modiﬁcation. The PCR
ampliﬁcation proﬁle was as follows: initial denaturation at 95 °C for 5 min, followed by 35 cycles of
denaturation at 95 °C for 20 s, gradient temperature annealing from 54.3 °C, 54.9 °C, 57.3 °C, 59.7 °C,
60.8 °C to 62.3 °C for 20 s, and extension at 72 °C for 30 s (Kyratec Super Cycler Thermal Cycler,
Australia). All PCR tubes, distilled water, pipette tips, and pipettes were pre-treated by exposing them
on UV-light for 715-20 minute prior to use. All PCR reagent mixing was done under laminar air ﬂow.
2.3. Sensitivity test of allele-speciﬁc PCR
Two genomic DNA with known SNPs (No.6 genomic DNA for AG genotype and DEV genomic DNA
for AA genotype) were ﬁxed at 50 ng/mL to make serial dilution ranging from 10 ng declining to
Fig. 3. Sensitivity test of allele-speciﬁc PCR in genotyping HER2I655V polymorphism. PCR was performed using optimized PCR
condition where annealing temperature was at 54.3 °C. NTC was Non-Template Control. The PCR product was run on 3%
agarose under UV illumination.
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optimum annealing temperature with PCR reagents and PCR ampliﬁcation proﬁle followed method
mentioned above.2.4. Validating and genotyping test using allele-speciﬁc PCR
Sixty-one samples of breast cancer were tested for HER2I655V polymorphism using optimized
allele-speciﬁc PCR. The PCR condition and temperature proﬁle were the same as mentioned above
except for annealing temperature was ﬁxed at 54.3 °C. The method was validated by direct Sanger
DNA sequencing of 61 sample of breast cancer patients by ﬁrstly ampliﬁed DNA fragment using
primer pairs HER2_F (50-CCAGCCCTCTGACGTCCAT-30) and HER2_R (50-TCCGTTTCCTGCAGCAGTCTCC-
30) generating 142 bp PCR product. The PCR ampliﬁcation proﬁle was as follows: initial denaturation
at 95 °C for 5 min, followed by 35 cycles of denaturation at 95 °C for 30 s, an nealing temperature at
60 °C for 30 s, and extension at 72 °C for 30 s. This PCR product was sequenced using HER2_R primer
only done by First-Base Asia Ltd.
Fig. 4. Allele-speciﬁc PCR of HER2I655V polymorphism for 10 of 61 samples of breast cancer patients. (A) Gel electrophoresis
data of allele-speciﬁc PCR: Yellow arrow head indicated AA genotype with band size of 142 bp; green arrow head indicated GG
genotype with band size of 168 bp; red arrows head indicated AA/GG genotype represented two different of PCR band pro-
ducts. The PCR product was run on 3% agarose under UV illumination. M is 100 bp DNA ladder meanwhile NTC (Non-template
control) was pointed in lane 11. (B) Sanger DNA sequencing chromatograms of HER2I655V polymorphism. Yellow arrow head
indicated AA genotype; green arrow head indicated GG genotype; red arrows head indicated AA/GG genotype. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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Table 1
Distribution data of HER2I655V polymorphism in two methods comparison.
Allelic types Methods
Sanger sequencing Allele-speciﬁc PCR
AA 37 (60.6%) 37 (60.6%)
GG 2 (3.3%) 2 (3.3%)
AG 22 (36.1%) 22(36.1%)
Failed 0 (0%) 0 (0%)
Total samples 61 (100%) 61 (100%)
Percentage means the number of samples produces correct genotype in total samples tested
Table 2
Genotype frequency of HER2I655V polymorphism showed by our data versus published data.
Author Year of
publication
Genotypes (%) Sample
population
P value
AA GG AG
Ile Val
Our experiment 60.6 3.3 36.1 Asian
Allele frequency 0.79 0.21
Xie et al. [5] 2000 71.7 3.2 25.1 Asian 40.05a
An et al. [6] 2005 78.5 2.8 18.6 Asian
Naidu et al. [7] 2008 71.7 3.4 24.7 Asian
Allele frequency 0.85 0.15
Keshava et al. [8] 2001 64.9 4.3 30.8 European 40.05b
Millikan et al. [9] 2003 59.6 6.3 34.02 European
Nelson et al. [10] 2005 58.2 5.6 36.2 European
Allele frequency 0.78 0.22
Millikan et al. [9] 2003 87.5 1.1 11.7 African o0.05c
Siddig et al. [11] 2008 82.4 1.5 16.2 African
kallel et al. [12] 2009 87.8 2.7 9.5 African
Allele frequency 0.92 0.08
Note: Each of P value represented the different of genotype frequency of HER2I655V obtained from Chi-Square test.
a no siginiﬁcant event was observed between genotype frequency of HER2I655V in our experiment with Asian population.
b no siginiﬁcant event was observed between genotype frequency of HER2I655V in our experiment with European popu-
lation.
c a siginiﬁcant event was observed between genotype frequency of HER2I655V in our experiment with African population.
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Data were tested for statistical signiﬁcance by using Statistical Package for the Social Sciences
software system SPSS-17 statistical software (SPSS, Chicago,IL). Frequency of each HER2I655V allele was
calculated using formulation frequency of Ile¼ f(Ile/Ile)þ0.5f(IleVal), whereas frequency of Val¼ f(Val/
Val)þ0.5f (IleVal). Chi-square test was used to analyze differences in genotype frequencies between
our data with published dataset to evaluate any possible deviation from Hardy–Weinberg equilibrium
of our genotyping data. Genotype frequencies are interpreted as statistically signiﬁcant different if
only the P value is less than 0.05 [4].Acknowledgments
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